한글목차

세계 림프부종 시장 규모는 2024년에 9억 8,985만 달러에 달했고, 2033년에는 20억 2,990만 달러에 달할 것으로 예상되며, 2025-2033년의 예측 기간 동안 8.8%의 연평균 복합 성장률(CAGR)을 보일 전망입니다.

림프부종이란 일반적으로 신체의 림프계를 통해 배출되는 단백질이 많이 함유된 체액이 축적되어 조직이 붓는 것을 말합니다. 림프부종은 팔과 다리에 가장 많이 발생하지만 흉벽, 복부, 경부, 생식기에도 발생할 수 있습니다. 림프부종은 림프절을 절제하거나 손상시키는 암 치료로 인해 발생할 수 있습니다. 림프액 배출을 방해하는 모든 원인은 림프부종을 유발할 수 있습니다.

시장 역학

성장 촉진요인과 억제요인

림프부종 치료 기술의 발전

세계 림프부종 시장 수요는 여러 요인에 의해 촉진되고 있습니다. 주요 요인 중 하나는 의료 시스템의 기술 발전입니다. 림프부종은 일반적으로 림프액 배출 부족으로 인해 발생하는 만성적인 증상입니다. 주요 기업의 혁신적인 기술 발전은 시장 성장을 가속합니다. 이러한 효과적인 발전은 연구 발견을 새로운 치료법으로 전환하여 수백만 명의 림프부종 환자의 치료를 개선하는 데 도움이 되고 있습니다.

예를 들어, 2022년 10월 임페디메드(ImpediMed Limited)는 주요 암센터에서 림프부종이 유방암 환자에게 미치는 영향을 줄이기 위해 자사의 SOZO 디지털 건강 플랫폼의 사용을 확대한다고 발표했습니다. 또한, 림프부종 치료에 대한 첨단 연구 개발을 도입하고 새로운 치료법과 의약품을 출시하는 주요 기업들이 이 시장의 성장을 가속할 것으로 보입니다.

또한, 림프부종 유병률 증가, 임상시험 증가, 인지도 향상, 신약 및 치료법 개발의 발전은 시장을 견인할 것으로 예상되는 요인입니다.

인식 부족

세계 림프부종 시장의 성장을 저해하는 주요 과제 중 하나는 환자와 의료진 모두에 대한 인식 부족입니다. 림프부종은 전 세계 수백만 명의 사람들에게 영향을 미치고 있음에도 불구하고 진단과 치료가 제대로 이루어지지 않아 개입이 늦어지고 건강 결과가 악화되고 있습니다.

많은 환자들이 부종, 무거움, 피부 변화 등의 초기 증상을 알아차리지 못해 진단이 늦어지는 경우가 많습니다. 림프부종을 지속적인 관리가 필요한 평생 만성질환이 아닌 일시적인 증상으로 오해하는 경우도 있습니다. 따라서 위의 요인들이 세계 림프부종 시장의 잠재적 성장을 제한할 수 있습니다.

이 보고서는 세계 림프부종 시장에 대해 조사했으며, 시장 역학, 지역 및 부문 분석, 경쟁 구도, 기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 시장 서론과 범위

제2장 주요 인사이트와 중요 사항

• 시장 하이라이트와 전략적 포인트
• 주요 동향과 향후 예측
• 발췌 : 유형별
• 발췌 : 치료 유형별
• 발췌 : 최종사용자별
• 발췌 : 지역별

제3장 시장 역학

• 영향요인
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 영향 분석

제4장 전략적 인사이트와 산업 전망

• 시장 리더와 선구자
  • 신흥 선구자와 저명 기업
  • 기존 리더와 가장 많이 판매되는 브랜드
  • 시장 리더와 기존 제품
• CXO의 견해
• 최신 발전과 Break through
• 사례 연구/진행중인 조사
• 규제와 상환 상황
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• Porter의 Five Forces 분석
• 공급망 분석
• 특허 분석
• SWOT 분석
• 미충족 요구와 갭
• 시장 진입 및 확장을 위한 권장 전략
• 시나리오 분석 : 베스트 케이스, 기본 케이스, 워스트 케이스 예측
• 가격 분석과 가격 동향
• KOL(Key Opinion Leader)

제5장 림프부종 시장 : 유형별

• 원발성 림프부종
• 연발성 림프부종

제6장 림프부종 시장 : 치료 유형별

• 약제 유형
  • Ketoprofen
  • Flucloxacillin
  • Amoxicillin
• Decongestive Lymphedema Therapy (DLT)
  • Manual Lymphatic Drainage (MLD)
  • 압축 디바이스
    • 압축 펌프
    • 압축 랩
    • 압축 스타킹
    • 압박대
• 수술
  • 감량 수술
  • Vascularized Lymph Node Transfer (VLNT)
  • Lymphaticovenous Anastomoses (LVA)
  • Suction-Assisted Protein Lipectomy (SAPL)
• 레이저 요법
• 기타

제7장 림프부종 시장 : 최종사용자별

• 병원
• 전문 클리닉
• 외래수술센터(ASC)
• 기타

제8장 림프부종 시장 : 지역별, 시장 분석과 성장 기회

• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타 유럽
• 라틴아메리카
  • 멕시코
  • 브라질
  • 아르헨티나
  • 기타 라틴아메리카
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타 아시아태평양
• 중동 및 아프리카

제9장 경쟁 구도와 시장 포지셔닝

• 경쟁 구도 개요와 주요 시장 기업
• 시장 점유율 분석과 포지셔닝 매트릭스
• 전략적 파트너십 및 인수합병(M&A)
• 제품 포트폴리오와 혁신 주요 발전
• 기업 벤치마킹

제10장 기업 개요

• Tactile Medical
• Bio Compression Systems, Inc.
• BSN-JOBST, Inc.
• Sigvaris group
• Lohmann & Rauscher(L&R)
• AIROS Medical, Inc.
• Arjo
• Venturelab Ltd.
• LymphaCare
• Absolute Medical, Inc.

제11장 전제조건과 조사 방법

제12장 부록

영문목차

The global lymphedema market reached US$ 989.85 million in 2024 and is expected to reach US$ 2,029.90 million by 2033, growing at a CAGR of 8.8 % during the forecast period of 2025-2033.

Lymphedema refers to tissue swelling caused by an accumulation of protein-rich fluid that's usually drained through the body's lymphatic system. It most commonly affects the arms or legs, but can also occur in the chest wall, abdomen, neck, and genitals. Lymphedema can be caused by cancer treatments that remove or damage the lymph nodes. Any cause that blocks the drainage of lymph fluid can lead to lymphedema.

Market Dynamics: Drivers & Restraints

Increasing Technological Advancements for Lymphedema Treatment

The demand for the global lymphedema market is driven by multiple factors. One of the key factors is the technological advancements in the healthcare system. Lymphedema is a chronic condition that is usually caused by insufficient lymphatic drainage. The innovative technological advancements by key companies help to drive market growth. These effective advancements help to transform research discoveries into new treatments and improve care for millions of people with lymphedema.

For instance, in October 2022, ImpediMed Limited announced the expansion of the use of its SOZO Digital Health Platform at leading cancer centers dedicated to reducing the impact of lymphedema on breast cancer patients. Moreover, key players introducing advanced research & developments in treating lymphedema and launching new therapies & drugs would drive this market growth.

Further, the increasing prevalence of lymphedema, increasing clinical trials, increasing awareness, and advancements in the development of novel drugs and therapies are the factors expected to drive the market.

Lack of Awareness

One of the significant challenges hindering the growth of the global lymphedema market is the lack of awareness among both patients and healthcare providers. Despite lymphedema affecting millions worldwide, it remains underdiagnosed and undertreated, leading to delayed intervention and poorer health outcomes.

Many patients are unaware of early symptoms, such as swelling, heaviness, or skin changes, leading to delayed diagnosis. Some people mistakenly believe lymphedema is a temporary condition rather than a lifelong chronic disease that requires continuous management. Thus, the above factors could be limiting the global lymphedema market's potential growth.

Segment Analysis

The global lymphedema market is segmented based on type, treatment type, end-user, and region.

Treatment Type:

The decongestive lymphedema therapy (DLT) segment in treatment type is expected to dominate the global lymphedema market with the highest market share

Decongestive lymphatic therapy (CDT) is used to provide permanent control of the volumetric and metaplastic tissue changes associated with lymphedema. The therapy includes manual lymphatic drainage and compression among others. Intermittent pneumatic compression pumps are used to treat lymphedema symptoms.

Decongestive lymphatic therapy (DLT) is the cornerstone of lymphedema management and a key segment of the global lymphedema treatment market. This multimodal approach combines compression therapy, manual lymphatic drainage, exercise, and skin care to reduce swelling and improve quality of life for patients with chronic fluid retention.

The companies are receiving approvals for advanced devices for patients with lymphedema. These advanced devices could help in maintaining the disease condition rather than making it worse. For instance, in March 2024, Extremit-Ease Compression Garment, by AMERX Health Care, received approval from PDAC for code A6583, one of the 78 new codes issued under the new Lymphedema Treatment Act (LTA). These factors have solidified the segment's position in the global lymphedema market.

Geographical Analysis

North America is expected to hold a significant position in the global lymphedema market with the highest market share

The region is expected to hold the dominant position during the forecast period, owing to the rising prevalence of lymphedema and rising breast cancer in the U.S. and Canada, driving the market growth. For instance, according to the Lymphatic Education & Research Network, it is stated that around 10 million Americans suffer from Lymphedema.

Additionally, the key strategies among the market players, such as collaboration partnerships and product launches, are also expected to propel the market growth. For instance, in June 2023, PAUL HARTMANN AG announced its partnership with Sigvaris for the innovative compression wraps and liners range that are used as compression therapy for the treatment of lymphedema. Thus, the above factors are consolidating the region's position as a dominant force in the global lymphedema market.

Competitive Landscape

The major global players in the lymphedema market include Tactile Medical, Bio Compression Systems, Inc., BSN-JOBST, Inc., Sigvaris group, Lohmann & Rauscher (L&R), AIROS Medical, Inc., Arjo, Venturelab Ltd., LymphaCare, and Absolute Medical, Inc., among others.

Key Developments

• In September 2023, AIROS Medical, Inc. announced the availability of the AIROS 6P sequential compression device and pants-like compression garments that treat abdominal, pelvic, and leg swelling. The company launched the AIROS 8P sequential compression device and similar garments earlier this year.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global lymphedema market report delivers a detailed analysis with 62 key tables, more than 54 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Type
• 2.4. Snippet by Treatment Type
• 2.5. Snippet by End-User
• 2.6. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Increasing Technological Advancements for Lymphedema Treatment
    • 3.1.1.2. Increasing Prevalence of Lymphedema
  • 3.1.2. Restraints
    • 3.1.2.1. Lack of Awareness
    • 3.1.2.2. High Cost of the Treatment Procedure
  • 3.1.3. Opportunity
    • 3.1.3.1. Increasing Personalized Treatments
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with the largest-selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia Pacific
  • 4.5.4. Latin America
  • 4.5.5. Middle East & Africa
• 4.6. Porter's Five Forces Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. Lymphedema Market, By Type

• 5.1. Introduction
  • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  • 5.1.2. Market Attractiveness Index By Type
• 5.2. Primary Lymphedema*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 5.3. Secondary Lymphedema

6. Lymphedema Market, By Treatment Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 6.1.2. Market Attractiveness Index By Treatment Type
• 6.2. Drug Type*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Ketoprofen
  • 6.2.4. Flucloxacillin
  • 6.2.5. Amoxicillin
• 6.3. Decongestive Lymphedema Therapy (DLT)
  • 6.3.1. Manual Lymphatic Drainage (MLD)
  • 6.3.2. Compression Devices
    • 6.3.2.1. Compression Pumps
    • 6.3.2.2. Compression Wraps
    • 6.3.2.3. Compression Stocking
    • 6.3.2.4. Compression Garments
• 6.4. Surgery
  • 6.4.1. Debulking Surgery
  • 6.4.2. Vascularized Lymph Node Transfer (VLNT)
  • 6.4.3. Lymphaticovenous Anastomoses (LVA)
  • 6.4.4. Suction-Assisted Protein Lipectomy (SAPL)
• 6.5. Laser Therapy
• 6.6. Others

7. Lymphedema Market, By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Hospitals*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Specialty Clinics
• 7.4. Ambulatory Surgical Centers
• 7.5. Others

8. Lymphedema Market, By Regional Market Analysis and Growth Opportunities

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.6.1. U.S.
    • 8.2.6.2. Canada
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.6.1. Germany
    • 8.3.6.2. U.K.
    • 8.3.6.3. France
    • 8.3.6.4. Spain
    • 8.3.6.5. Italy
    • 8.3.6.6. Rest of Europe
• 8.4. Latin America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.6.1. Mexico
    • 8.4.6.2. Brazil
    • 8.4.6.3. Argentina
    • 8.4.6.4. Rest of Latin America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.6.1. China
    • 8.5.6.2. India
    • 8.5.6.3. Japan
    • 8.5.6.4. South Korea
    • 8.5.6.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

• 9.1. Competitive Overview and Key Market Players
• 9.2. Market Share Analysis and Positioning Matrix
• 9.3. Strategic Partnerships, Mergers & Acquisitions
• 9.4. Key Developments in Product Portfolios and Innovations
• 9.5. Company Benchmarking

10. Company Profiles

• 10.1. Tactile Medical*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
    • 10.1.2.1. Product Description
    • 10.1.2.2. Product Key Performance Indicators (KPIs)
    • 10.1.2.3. Historic and Forecasted Product Sales
    • 10.1.2.4. Product Sales Volume
  • 10.1.3. Financial Overview
    • 10.1.3.1. Company Revenue
    • 10.1.3.2. Geographical Revenue Shares
    • 10.1.3.3. Revenue Forecasts
  • 10.1.4. Key Developments
    • 10.1.4.1. Mergers & Acquisitions
    • 10.1.4.2. Key Product Development Activities
    • 10.1.4.3. Regulatory Approvals, etc.
  • 10.1.5. SWOT Analysis
• 10.2. Bio Compression Systems, Inc.
• 10.3. BSN-JOBST, Inc.
• 10.4. Sigvaris group
• 10.5. Lohmann & Rauscher (L&R)
• 10.6. AIROS Medical, Inc.
• 10.7. Arjo
• 10.8. Venturelab Ltd.
• 10.9. LymphaCare
• 10.10. Absolute Medical, Inc.

LIST NOT EXHAUSTIVE

11. Assumptions and Research Methodology

• 11.1. Data Collection Methods
• 11.2. Data Triangulation
• 11.3. Forecasting Techniques
• 11.4. Data Verification and Validation

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us